Work

Safety and efficacy of endoscopic sleeve gastroplasty after liver transplantation

Year: 2025

Type: article

Abstract: Background and Aims Obesity after liver transplantation (LT) can compromise patient outcomes. We report safety and efficacy data on endoscopic sleeve gastroplasty (ESG) after LT. Methods This is a retrospective case series of patients who underwent ESG after LT. Results All 5 patients underwent ESG at a median 47.3 months (interquartile range [IQR], 34.4-67.4 months) after LT. Patients were predominantly male (4/5, 80%) with median age 61 years (IQR, 51-61 years) and preoperative body mass index 38.8 kg/m 2 (IQR, 37.1-42.6 kg/m 2 ). Median follow-up after ESG was 18.8 months (IQR, 8.2-19.8 months). Median total body weight loss was 27.2% (IQR, 8.0%-30.0%) at the end of follow-up. Weight loss plateau occurred in 2 patients, with 5 postoperative adverse events in 4 patients (80%) that were mild, and none exceeded grade I on the Clavien-Dindo scale. No patient missed doses of immunosuppressive medications. Liver graft function remained stable. Conclusions Our data support the use of ESG after LT, although more data are needed to validate our findings.

Source: iGIE

DOI: 10.1016/j.igie.2025.03.013